A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with early hepatocellular carcinoma

被引:29
作者
Yan, Bing [1 ,2 ]
Su, Bing-Bing [1 ]
Bai, Dou-Sheng [1 ]
Qian, Jian-Jun [1 ]
Zhang, Chi [1 ]
Jin, Sheng-Jie [1 ]
Jiang, Guo-Qing [1 ]
机构
[1] Yangzhou Univ, Clin Med Coll, Dept Hepatobiliary Surg, 98 West Nantong Rd, Yangzhou 225000, Jiangsu, Peoples R China
[2] Dalian Med Univ, Clin Coll 2, Dept Hepatobiliary Surg, Dalian, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 02期
关键词
cancer‐ specific survival; hepatocellular carcinoma; nomogram; predict; risk stratification; STAGING-SYSTEM; UNITED-STATES; EXTERNAL VALIDATION; SURGICAL THERAPY; RESECTION;
D O I
10.1002/cam4.3613
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Our purpose was to establish and validate a nomogram model in early hepatocellular carcinoma (HCC) patients for predicting the cancer-specific survival (CSS). Methods We extracted eligible data of relevant patients between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Further, we divided all patients into two groups (training and validation cohorts) at random (7:3). Nomogram was established using effective risk factors based on univariate and multivariate analysis. The effective performance of nomogram was evaluated using concordance index (C-index), calibration plots, decision curve analysis (DCA), and receiver operating characteristic curve (ROC). Results We selected 3620 patients with early HCC including the training cohort (70%, 2536) and the validation cohort (30%, 1084). The nomogram-related C-indexes were 0.755 (95% CI: 0.739-0.771) and 0.737 (95% CI: 0.712-0.762), in the training and validation cohorts, respectively. The calibration plots showed good consistency of 3-and 5-year CSS between the actual observation and the nomogram prediction. The 3-, 5-year DCA curves also indicated that the nomogram has excellent clinical utility. The 3-, 5-year area under curve (AUC) of ROC in the training cohort were 0.783, 0.779, respectively, and 0.767, 0.766 in the validation cohort, respectively. With the establishment of nomogram, a risk stratification system was also established that could divide all patients into three risk groups, and the CSS in different groups (i.e., low risk, intermediate risk, and high risk) had a good regional division. Conclusions We developed a practical nomogram in early HCC patients for predicting the CSS, and a risk stratification system follow arisen, which provided an applicable tool for clinical management.
引用
收藏
页码:496 / 506
页数:11
相关论文
共 33 条
  • [1] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Reichman, Marsha E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
  • [2] Nomograms in oncology: more than meets the eye
    Balachandran, Vinod P.
    Gonen, Mithat
    Smith, J. Joshua
    DeMatteo, Ronald P.
    [J]. LANCET ONCOLOGY, 2015, 16 (04) : E173 - E180
  • [3] NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines
    Benson, Al B., III
    D'Angelica, Michael I.
    Abbott, Daniel E.
    Abrams, Thomas A.
    Alberts, Steven R.
    Saenz, Daniel Anaya
    Are, Chandrakanth
    Brown, Daniel B.
    Chang, Daniel T.
    Covey, Anne M.
    Hawkins, William
    Iyer, Renuka
    Jacob, Rojymon
    Karachristos, Andrea
    Kelley, R. Kate
    Kim, Robin
    Palta, Manisha
    Park, James O.
    Sahai, Vaibhav
    Schefter, Tracey
    Schmidt, Carl
    Sicklick, Jason K.
    Singh, Gagandeep
    Sohal, Davendra
    Stein, Stacey
    Tian, G. Gary
    Vauthey, Jean-Nicolas
    Venook, Alan P.
    Zhu, Andrew X.
    Hoffmann, Karin G.
    Darlow, Susan
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (05): : 563 - 573
  • [4] Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA):: a prospective study
    Cammà, C
    Di Marco, V
    Orlando, A
    Sandonato, L
    Casaril, A
    Parisi, P
    Alizzi, S
    Sciarrino, E
    Virdone, R
    Pardo, S
    Di Bona, D
    Licata, A
    Latteri, F
    Cabibbo, G
    Montalto, G
    Latteri, MA
    Nicoli, N
    Craxì, A
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (04) : 535 - 540
  • [5] A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma
    Chen, Jinbin
    Fang, Aiping
    Chen, Minshan
    Tuoheti, Yiminjiang
    Zhou, Zhongguo
    Xu, Li
    Chen, Jiancong
    Pan, Yangxun
    Wang, Juncheng
    Zhu, Huilian
    Zhang, Yaojun
    [J]. CANCER MEDICINE, 2018, 7 (10): : 5027 - 5035
  • [6] A Simple-to-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients
    Chen, Si-Hai
    Wan, Qin-Si
    Zhou, Di
    Wang, Ting
    Hu, Jia
    He, Yu-Ting
    Yuan, Hai-Liang
    Wang, Yu-Goi
    Zhang, Kun-He
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma
    Chun, Yoon Hee
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Han, Kwang-Hyub
    Chon, Chae Yoon
    Kim, Beom Kyung
    Choi, Gi Hong
    Kim, Kyung Sik
    Choi, Jin Sub
    Ahn, Sang Hoon
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) : 2568 - 2575
  • [8] Racial differences in survival of hepatocellular carcinoma in the United States: A population-based study
    Davila, JA
    El-Serag, HB
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (01) : 104 - 110
  • [9] Diagnosis and treatment of hepatocellular carcinoma
    El-Serag, Hashem B.
    Marrero, Jorge A.
    Rudolph, Lenhard
    Reddy, K. Rajender
    [J]. GASTROENTEROLOGY, 2008, 134 (06) : 1752 - 1763
  • [10] Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go?
    El-Serag, Hashem B.
    Kanwal, Fasiha
    [J]. HEPATOLOGY, 2014, 60 (05) : 1767 - 1775